New strategy aims to stop rapid bone loss after stopping osteoporosis drug
NCT ID NCT07281586
First seen Jan 04, 2026 · Last updated May 14, 2026 · Updated 25 times
Summary
This study tests whether a step-down approach—using half-dose denosumab (Prolia) combined with zoledronic acid (Aclasta)—can better prevent bone loss in people who have been on denosumab for at least three years. The trial includes 44 postmenopausal women and men aged 50–85 with osteoporosis or related fractures. The goal is to find a safer way to stop treatment without losing bone density.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Taiwan University Hospital Yunlin Branch
RECRUITINGDouliu, Taiwan, 640, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.